Foghorn Therapeutics Inc Q3 2024 Earnings Revenue Surpasses Estimates at 7. ... Revenue Reported 7.8 million for Q3 2024, surpassing the analyst estimate of 6.34 million, driven by the Lilly Collaboration Agreement.Net Loss Increased t

Foghorn Therapeutics Inc Q3 2024 Earnings Revenue Surpasses Estimates at 7. ...

FHTX Stock  USD 4.30  0.25  6.17%   
Slightly above 58% of Foghorn Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Foghorn Therapeutics suggests that many traders are alarmed. Foghorn Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Foghorn Therapeutics' earnings reports, geopolitical events, and overall market trends.
Revenue Reported 7.8 million for Q3 2024, surpassing the analyst estimate of 6.34 million, driven by the Lilly Collaboration Agreement.Net Loss Increased t

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Foghorn Therapeutics Current Investor Sentiment

Comfort Level 42

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Foghorn Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Foghorn Therapeutics.

Foghorn Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Foghorn Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Foghorn Therapeutics Historical Investor Sentiment

Investor biases related to Foghorn Therapeutics' public news can be used to forecast risks associated with an investment in Foghorn. The trend in average sentiment can be used to explain how an investor holding Foghorn can time the market purely based on public headlines and social activities around Foghorn Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Foghorn Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Foghorn Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Foghorn Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Foghorn Therapeutics.

Foghorn Therapeutics Fundamental Analysis

We analyze Foghorn Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Asset

Return On Asset Comparative Analysis

Foghorn Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Foghorn Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Foghorn Therapeutics stock to make a market-neutral strategy. Peer analysis of Foghorn Therapeutics could also be used in its relative valuation, which is a method of valuing Foghorn Therapeutics by comparing valuation metrics with similar companies.

Peers

Foghorn Therapeutics Related Equities

PRLDPrelude Therapeutics   8.75   
0%
91.0%
CSBRChampions Oncology   3.10   
0%
32.0%
NRIXNurix Therapeutics   2.76   
0%
28.0%
GLUEMonte Rosa   2.27   
0%
23.0%
RZLTRezolute   1.54   
0%
16.0%
STOKStoke Therapeutics   0.75   
0%
7.0%
MNOVMediciNova   0.71   
0%
7.0%
CGEMCullinan Oncology   0.38   
0%
3.0%
MOLNMolecular Partners   0.25   
0%
2.0%
MLYSMineralys Therapeutics,   0.75   
7.0%
0%
PMVPPmv Pharmaceuticals   1.10   
11.0%
0%
EWTXEdgewise Therapeutics   1.55   
16.0%
0%
IPSCCentury Therapeutics   1.75   
18.0%
0%
KYMRKymera Therapeutics   2.34   
24.0%
0%
ANEBAnebulo Pharmaceuticals   4.42   
46.0%
0%
CCCCC4 Therapeutics   8.70   
90.0%
0%
STTKShattuck Labs   9.57   
100.0%
0%

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.